EP2387388A1 - Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci - Google Patents

Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci

Info

Publication number
EP2387388A1
EP2387388A1 EP10701731A EP10701731A EP2387388A1 EP 2387388 A1 EP2387388 A1 EP 2387388A1 EP 10701731 A EP10701731 A EP 10701731A EP 10701731 A EP10701731 A EP 10701731A EP 2387388 A1 EP2387388 A1 EP 2387388A1
Authority
EP
European Patent Office
Prior art keywords
composition
tablet
tablet according
progesterone receptor
receptor modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10701731A
Other languages
German (de)
English (en)
Inventor
Pascal Prinderre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelgyn
Original Assignee
Exelgyn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelgyn filed Critical Exelgyn
Priority to EP10701731A priority Critical patent/EP2387388A1/fr
Publication of EP2387388A1 publication Critical patent/EP2387388A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the invention relates to novel Selective Progesterone Receptor Modulator (SPRM) compositions and to methods of treatment using them, especially where the SPRM is mifepristone.
  • SPRM Selective Progesterone Receptor Modulator
  • BACKROUND OF THE INVENTION Mifepristone also known as RU486 has the chemical formula ll ⁇ - [p- (Dimethylamino) phenyl] -17 ⁇ -hydroxy-17- (1- propynyl) estra-4, 9-dien-3-o n e , and is an important antiprogestin that effectively and safely terminates early pregnancy, when used in conjunction with a prostaglandin.
  • Mifepristone is commercially available in a dose of 3 tablets of 200 mg under the trade name Mifegyne".
  • a prostaglandin is administered 36 to 48 hours afterwards.
  • Leiomyomata are common pelvic fibroid tumors occurring in up to 20% of women over 30 years of age. Leiomyomata represent one of the most frequent indications of operative procedures in woman of reproductive age. Symptoms are reported in twenty to fifty percent of cases of leiomyomata and include pelvic pain, excessive duration or amount of menstruation, infertility and pelvic masses. The anti-progestin activity of mifepristone inhibits the growth of such tumors. The dosage for this therapeutical treatment is however far different from the dosage for termination of pregnancy. Indeed, the dosage is about 25 mg per day, especially 2 to 20 mg per day and preferably 5 mg per day.
  • Formulations to avoid the misuse of drugs are already disclosed in Canadian Patent Application CA 2,029,940, which relates to retentive delivery devices in the form of an t i oe s t r oge n or an t ipr o ge s t i n containing injectable microspheres. These are injected under the skin, and release a constant amount of an antioestrogen or antiprogestin over a period of 1 to 3 months, avoiding by the same way any overdosage or the misuse of the drug by the patient.
  • this Application does not disclose oral formulations, nor consider mifepristone as an antiprogestin within the scope of the invention.
  • the invention aims at providing novel compositions comprising Selective Progesterone Receptor Modulator (SPRM) and novel methods of treatment using them, which have the ability to prevent the intake of the composition by the patient in an abortive amount and avoid their misuse.
  • SPRM Selective Progesterone Receptor Modulator
  • the invention thus aims at providing compositions and methods which brings one or more of the following advantages: - the compositions exhibit a swelling into the stomach, such that unpleasant feeling is obtained when a low amount, especially three, unitary dosage forms are taken by the patient .
  • the compositions contain a laxative component in such an amount that the patient would feel uncomfortable as soon as the number of compositions taken reaches a low number, especially three compositions.
  • the composition contains an excipient of a nature and content such that this will prevent misuse (or misusage) of the mifepristone or SPRM active ingredient.
  • a first aspect of the invention is directed to a composition containing mifepristone or a Selective Progesterone Receptor Modulator (SPRM) in a non abortive amount and at least one excipient of a nature and content such that it prevents the intake of tablets by the patient in an abortive amount.
  • SPRM Selective Progesterone Receptor Modulator
  • the quantity of mifepristone or SPRM is from 1 to 25 mg, preferably from 2 to 10 mg, and more preferably 5 mg.
  • the at least one excipient is a laxative.
  • the at least one excipient is a laxative selected from the group comprising bisacodyl, cascara, docusate, disodic or monosodic phosphate, glycerin, lactulose, magnesium citrate, magnesium hydroxide, methylcellulose, mineral oil, psyllium, matamucil, senna, sorbitol and mixtures thereof.
  • the invention is directed to a composition containing a Selective Progesterone Receptor
  • Modulator in a non abortive amount and at least one excipient of a nature and content such that it prevents the intake of the composition by the patient in an abortive amount.
  • the quantity of SPRM is from 1 to 25 mg, preferably from 2 to 10 mg, and more preferably 5 mg.
  • the composition is a tablet.
  • the Selective Progesterone Receptor Modulator is mifepristone.
  • the invention is directed to a tablet for oral administration comprising 1 to 25 mg of Selective Progesterone Receptor Modulator, and from 200 to 2500 mg of the at least one excipient.
  • the tablet for oral administration comprises preferably from 5 to 10 mg of Selective Progesterone Receptor Modulator, and from 300 to 1000 mg of the at least one excipient.
  • the Selective Progesterone Receptor Modulator is mifepristone.
  • the tablet for oral administration comprises a swelling agent.
  • the swelling agent is selected from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose having molecular weight from 2, 000 to 2, 000, 000, carboxyvinyl polymers, polyvinyl alcohols, glucans, scleroglucans, chitosans, mannas, galactomannans, xantangums, carrageenans, amylase, alginic acid and salts therof, acrylates, methacrylates, acrylic/methacrylic copolymers, polyanhydrides, polyamino acids, methyl vinyl ethers/maleic anhydride copolymers, carboxymethylcellulose and derivatives thereof, ethylcellulose, methylcellulose and derivatives of cellulose, superporous hydrogels and mixtures thereof.
  • the Selective Progesterone Receptor Modulator can be released according to an immediate, sustained and controlled release.
  • the tablet for oral administration has a dissolution in a 1000 ml USP HCl buffer at pH 1.2, using the paddles method at 75 rpm, of at least 20% at 1 hour, at least 50% at 4 hours and at least 60% at 7 hours, and preferably of at least 30% at 1 hour, 70% at 4 hours and 80% at 7 hours.
  • the tablet for oral administration comprises at least partially swellable hydrophilic polymers in aqueous media, optionally in combination with other adjuvants and further comprising a SPRM, preferably mifepristone, in a single core.
  • a SPRM preferably mifepristone
  • the invention is directed to a process for the preparation of a tablet according to any one of claims 5 to 12 comprising at least a step of direct compression .
  • the process comprises a step of blending the Selective Progesterone Receptor
  • the composition or tablet is for the treatment of gynaecological diseases .
  • the composition or tablet is for the treatment of fibroid tumors.
  • the composition or tablet is for the treatment of leiomyomata.
  • Figure 1 represents a photograph of two of the tablets of example 1 at a swollen and non-swollen state.
  • Figure 2 represents a photograph of agglomerated and non agglomerated tablets of example 2.
  • Figure 3 represents a comparison of the dissolution rate for a single tablet or three tablets of F8, according to example 3.
  • Figure 4 represents the dissolution profile of tablet F14, according to example 4.
  • the invention relates to novel galenic formulations of mifepristone or other Selective Progesterone Receptor Modulator (SPRM) , used to medically treat uterine fibroid tumors such as leiomyomata.
  • SPRM Selective Progesterone Receptor Modulator
  • the invention relates to a composition or tablet composition containing between 5 and 50 mg of mifepristone or SPRM, especially 2 to 20 mg and preferably 5 mg, together with an excipient preventing misuse of mifepristone.
  • said excipient is a laxative.
  • the type and amount of laxative in the unitary dosage form is such that unpleasant feeling will be observed when e.g. 3 compositions are taken by the patient.
  • laxative compounds are: bisacodyl sold under the trade name Dulcolax®, cascara, docusate sold under the trade name Colace®, disodic or monosodic phosphate also sold under the trade name fleet phospho-soda®, glycerin, lactulose, magnesium citrate, magnesium hydroxide, methylcellulose sold under the trade name Citrucel®, mineral oil, psyllium, metamucil, senna sold under the trade name Senokot® or sorbitol.
  • said excipient provides a GRDF (gastro-retentive delivery form) type composition by swelling (or otherwise expanding) when in contact with the gastric juice present in the stomach.
  • the swelling can notably be such that the swelling ratio (or swelling percentage) is more than 50%, preferably more than 90%, especially more than 200%.
  • compositions of the present invention provide dosage forms that expand to sufficient size to delay its passage through the pylorus.
  • the core, a first layer surrounding the core or an outer layer contains water-swellable excipient and/or the active ingredient.
  • the outer layer may further contain a material having bioadhesive properties allowing the positioning and adhesion of pharmaceutical form to the mucosa of the first portion of the gastrointestinal tract.
  • the layers may also contain gas forming agents, which can optionally be employed to increase the buoyancy. These agents, when in contact with an aqueous media, form a non toxic gas, decrease the density of the pharmaceutical form, and provide floating properties to prolong the gastric residence time into the stomach. Examples of gas forming agents are sodium hydrogen carbonates employed individually or in combination with acids.
  • the GRDF is used for its ability to remain in a swollen state in the stomach which prevents the intake of numerous dosage forms, leading necessarily to a fast filling of the stomach. Steric hindrance will thus prevent intake of further dosage forms, and avoid reaching abortive doses of SPRM such as mifepristone.
  • the expansion of the GRDF occurs in less than 15 minutes, preferably less than 10 minutes and more preferably less than 5 minutes.
  • the swelling causes retention of the pharmaceutical dosage forms in the stomach for three hours or more, more preferably about four hours or more, after which time the drug delivery vehicle either dissolves or degrades into fragments small enough to pass the pylorus.
  • the layers may be designed to provide an immediate, sustained or controlled release of the active ingredient into the stomach. Eventhough a rapid delivery of the drug is usually preferred, it may also be advantageous within the scope of the present invention to design layers that provide a prolonged delivery of the drug in order to avoid misusage of the tablets encountered with the intake of several immediate release tablets at a rate of one tablet per minute for example.
  • a laxative may further be coated to the sustained or controlled release forms, in order to have an immediate release of the laxative together with a prolonged delivery of the SPRM.
  • GRDF General Retentive drug delivery systems
  • steric hindrance may also be obtained with tablets that in a non swollen state already have an important size. This way, the evacuation of the tablet via the duodenum as soon as it is swallowed by the patient may be avoided.
  • tablets according to the present invention may have any of the following structures: a) a unique core comprising at least partially swellable hydrophilic polymers in aqueous media, optionally in combination with other adjuvants and further comprising the SPRM active ingredient such as mifepristone.
  • a core and eventually a first layer any of which comprises at least partially swellable hydrophilic polymers in aqueous media, optionally in combination with other adjuvants, at least another layer adjacent to the core or first layer and containing mifepristone or a SPRM in a non abortive amount, comprising generally biodegradable and biocompatible polymeric materials a binder and other adjuvants, whereby the mifepristone or SPRM can be released according to an immediate, sustained and controlled release.
  • Suitable active ingredients may be any Selective Progesterone
  • SPRM Receptor Modulators
  • progesterone receptor ligands such as progesterone receptor ligands and encompass broadly any progesterone agonists or antagonists.
  • Suitable active ingredients are those that are useful in the treatment of fibroid tumors and especially leiomyomata.
  • members of SPRM include asoprisnil (J867) and active compounds of the Progenta®, and the Ulipristal® products such as CDB-4124 PGL-4001 and PGL-2001.
  • a most preferred SPRM is mifepristone, and especially micronized mifepristone.
  • the d50 of the micronized form is generally less than 30 ⁇ m, preferably less than 20 ⁇ m.
  • the polymeric substances used to prepare the swellable first layer are selected from the group consi sting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose having molecular weight from 2,000 to 2,000,000, carboxyvinyl polymers, polyvinyl alcohols, glucans, scleroglucans , chitosans, mannas, galactomannans, xantangums, carrageenans, amylase, alginic acid and salts therof, acrylates, methacrylates, acrylic/methacrylic copolymers, polyanhydrides, polyamino acids, methyl vinyl ethers/maleic anhydride copolymers, carboxymethylcellulose and derivatives thereof, ethylcellulose, methylcellulose and derivatives of cellulose in general, superporous hydrogels in general and mixtures thereof.
  • Adjuvant includes any of the following components binder, diluent, disintegrating agent, lubricant and anti-static agent and optionally other auxiliary agents, such as surfactants.
  • diluent means any excipient which acts to dilute the formulation without undergoing a chemical reaction with the formulation components.
  • a diluent of the invention includes generally inert carriers or vehicles, be it crystalline or amorphous. Examples of such diluents are derivatives of sugars, such as lactose, saccharose, mannitol, etc., and mixtures thereof. Microcristalline cellulose, its derivatives, and hydrolyzed starch (malto-dextrine) can be used, preferably in low amounts.
  • disintegrating agent means any excipient which exerts an action of disintegrating when the tablet is in an aqueous environment by facilitating the interaction between the components of the layer and the biological fluids, i.e. which exerts an internal pressure leading to breaks in the tablet and ultimately to its disintegration.
  • disintegrating agents of the invention are cross linked polyvinylpyrrolidone, hydroxypropylcellulose and hydroxypropyl methylcellulose having molecular weight up to 150,000, cross linked sodium carboxymethylcellulose, carboxymethyl starch, sodium carboxymethyl starch, potassium me t hacr y 1 a t e- divinylbenzene copolymer, polyvinyl alcohols, amylase, cross linked amylase, sodium starch glycollate starch derivatives, microcrystalline cellulose and cellulose derivatives, alpha, beta, and gamma-cyclodextrin and dextrin derivatives in general, pregelatinized starch and mixtures thereof.
  • compositions within the scope of the invention may also have if desired, additional properties that are useful to prevent misusage. Indeed, when several tablets are taken at the same time or at an inappropriate rate, compositions can be chosen so that they stick and agglomerate to each others when gathered in the stomach of the patients. Examples of appropriate excipients that provide sticking properties are any binder such as povidone, sacharrose, or glucose and any soluble diluent such as lactose, sorbitol or mannitol.
  • this has the advantage of significantly lowering the surface of exchange with the outer environment of the agglomerated tablets, and thereby challenges the delivery of the total amount of active ingredient that was absorbed and might be dangerously elevated.
  • the agglomeration of tablets results in an increased hindrance, having a size that delays its degradation prior to the evacuation through the pylorus. Preventive properties against misusage may then be enhanced if such properties are conferred to the composition of the present invention.
  • compositions according to the invention can be prepared conventionally.
  • compositions according to the invention may be prepared by dry blending and formulations may be reached through direct compression or dry granulation techniques.
  • the SPRM such as mifepristone is present in low amounts, it may be convenient to first blend the active ingredient with part of one or more of the excipients of a similar or close granulometry .
  • direct compression techniques involve excipients having a size of more than 60 ⁇ m, while the useful active ingredients can have smaller grades.
  • Micronized mifepristone may for example, consist in 90% of 15 ⁇ m particles. In this eventuality, it becomes convenient to preliminarily blend part of one of more of the excipients provided with a particle size of less than 60 ⁇ m.
  • the excipient is provided with a particle size that is similar or close to the particle size of the active ingredient, within a range that would be considered by the man skilled in the art.
  • micronized mifepristone when used, it may be blended with lactose (lactochem microfine®) having a particle size of less than 60 ⁇ m, preferably less than 30 ⁇ m and more preferably of less than 20 ⁇ m.
  • lactose lactochem microfine®
  • the preliminary blend appears to be less necessary than in the previous situation.
  • lactose appeared to be typically appropriate since it is available in a wide range of powdery grades .
  • granulation (dry, wet or melt) techniques may be particularly useful in the case where the amount of active ingredient is very low, such as less than 1% of the total weight, less than 0.5% or less than 0.1% of active ingredient.
  • the disintegrating excipients may be incorporated at the end of the granulation in order to avoid their contact with water and allow the concentration of the active ingredient.
  • the blended composition is compacted prior to hydration, by conventional means of dry granulation or direct compression techniques.
  • Mifepristone may be added after comminution of the compacted composition resulting in the mifepristone being extragranular .
  • the blended composition may be compressed directly into the final pharmaceutical dosage form using direct compression techniques. It produces a more uniform tablet without granules.
  • the oral dosage forms according to the invention may have a layered construction wherein mifepristone or the SPRM, alone or with other adjuvants, forms an outer layer that is bonded by compression to the other layers formed of the drug delivery vehicle as defined.
  • the SPRM may directly be compressed with the other excipients into a single core by direct compression techniques.
  • further adjuvants suited to direct compression, can be added such as lubricants, anti-static agents or glidants.
  • the expression "lubricant” means any excipient which ease ejection of the tablet from the tableting dye in which it is formed by compression and improves the flow properties of the composition in powder or granule.
  • examples of lubricants are talc, magnesium stearate and glyceryl behenate, and mixtures thereof.
  • antistatic agent means any excipient which exerts an anti-static action.
  • examples of antistatic agents are anhydrous colloidal silica (which may also act as a disintegrant) .
  • glidant means any excipient which essentially improves the flow properties of the composition in powder or granule form.
  • An example of glidants is silicon dioxide.
  • the formulation according to the invention can be prepared by conventional techniques. Therefore, their production on an industrial scale is easily available.
  • compositions were prepared and formulated in tablet forms by direct compression techniques according to a
  • D12PC format although different other formats may be appropriate, such as an oblong format (16x10 mm) . All of the forms have a total weight of 490 mg, contain 5 mg of mifepristone, and the composition is expressed in percentage of the total weight of the composition.
  • Example 1 Study of the swelling properties for the prepared forms .
  • the following test evaluated the swelling properties of the compositions according to the present invention into the stomach once swallowed.
  • the swelling percentage is given using the formula:
  • Example 3 Dissolution of the F8 tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles compositions comprenant un modulateur sélectif des récepteurs de la progestérone (SPRM) et de nouvelles méthodes de traitement les utilisant, qui ont la capacité d'empêcher l'absorption de la composition par le patient en une quantité abortive et d'éviter leur mauvais usage.
EP10701731A 2009-01-16 2010-01-11 Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci Withdrawn EP2387388A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10701731A EP2387388A1 (fr) 2009-01-16 2010-01-11 Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290034A EP2210585A1 (fr) 2009-01-16 2009-01-16 Compositions pharmaceutiques SPRM et procédés de traitement les utilisant
EP10701731A EP2387388A1 (fr) 2009-01-16 2010-01-11 Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci
PCT/IB2010/050078 WO2010082149A1 (fr) 2009-01-16 2010-01-11 Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci

Publications (1)

Publication Number Publication Date
EP2387388A1 true EP2387388A1 (fr) 2011-11-23

Family

ID=40627453

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09290034A Withdrawn EP2210585A1 (fr) 2009-01-16 2009-01-16 Compositions pharmaceutiques SPRM et procédés de traitement les utilisant
EP10701731A Withdrawn EP2387388A1 (fr) 2009-01-16 2010-01-11 Compositions pharmaceutiques sprm et méthodes de traitement utilisant celles-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09290034A Withdrawn EP2210585A1 (fr) 2009-01-16 2009-01-16 Compositions pharmaceutiques SPRM et procédés de traitement les utilisant

Country Status (2)

Country Link
EP (2) EP2210585A1 (fr)
WO (1) WO2010082149A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20120127A1 (it) * 2012-06-21 2013-12-22 Valpharma Internat Spa Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio, compresse così ottenute e loro processo di preparazione.
ITFI20120128A1 (it) * 2012-06-21 2013-12-22 Valpharma Internat Spa Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio per il trattamento di endometriosi, compresse così ottenute e loro processo di preparazione.
EP2868321A1 (fr) 2013-11-03 2015-05-06 Flamina Holding AG Composition ou groupe des compositions pour l'inhibitation de la production de HCG autocrine dans la cellulse adulte humain
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868320A1 (fr) * 2013-11-03 2015-05-06 Flamina Holding AG Composition ou groupe de compositions pour le traitement de cellules humaines
WO2023033900A1 (fr) * 2021-09-06 2023-03-09 Slayback Pharma Llc Compositions pharmaceutiques de mifépristone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
GB8630876D0 (en) 1986-12-24 1987-02-04 Graham N B Hydrogel-containing envelopes
FR2654337B1 (fr) 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US20030008007A1 (en) 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
CA2409552A1 (fr) 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
WO2005094821A1 (fr) * 2004-03-30 2005-10-13 Lotus Pharmaceutical Co.,Ltd. Composition medicale pour augmenter la securite d'un medicament
WO2007103510A2 (fr) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methodes, regimes posologiques et medicaments utilisant des agents antiprogestatifs dans le traitement de certains troubles
EP1987814A1 (fr) * 2007-04-30 2008-11-05 Exelgyn Compositions pharmaceutiques de mifepristone et leurs procédé de préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010082149A1 *

Also Published As

Publication number Publication date
EP2210585A1 (fr) 2010-07-28
WO2010082149A1 (fr) 2010-07-22

Similar Documents

Publication Publication Date Title
US11793760B2 (en) Orodispersible dosage unit containing an estetrol component
JP6151727B2 (ja) ウリプリスタール酢酸エステル錠
EP3079671B1 (fr) Unité posologique solide à désintégration orale contenant un composant d'estétrol
JP2000044490A (ja) アクリル型ポリマ―の崩壊剤としての使用
TW201022253A (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
RU2678695C2 (ru) Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита
EP2210585A1 (fr) Compositions pharmaceutiques SPRM et procédés de traitement les utilisant
KR20180021085A (ko) 에스테트롤 성분을 함유하는 구강분해성 투여 단위
JP2014193878A (ja) トラネキサム酸製剤
CN102210871A (zh) 缓释释药的药物载体
TW201832767A (zh) 治療婦科疾病之組合物
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
JP3836893B2 (ja) ポリカルボフィルカルシウム含有製剤
US20220347145A1 (en) Misoprostol Dispersible Tablet
AU7525000A (en) Treating endometriosis or infertility, or improving fertility
US10688072B2 (en) Misoprostol dispersible tablet
CA2689987A1 (fr) Composition pharmaceutique d'un nouveau systeme destine a la liberation de steroides dans le vagin
EP2965750B1 (fr) Comprimé dispersible de misoprostol
Siddeswar Formulation and Evaluation of Fluconazole Muco-Adhesive Vaginal Tablets

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110811

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130801